Doctors' Understanding of Survival Statistics (MPIB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00981019|
Recruitment Status : Completed
First Posted : September 22, 2009
Results First Posted : August 15, 2011
Last Update Posted : August 15, 2011
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||778 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Study of Primary Care Physicians' Understanding and Use of Different Survival Measures|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
mortality*incidence*5-year survival*early stage
Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
- Number of Physicians (=Participants) Recommending the Screening [ Time Frame: 25 minutes (mean duration of the survey) ]The aim of the study was to learn how different medical cancer screening statistics would influence doctors' recommendation behavior and their effectiveness judgments of screening tests. For that reason the online survey study presented physicians with four different medical statistics (e.g., 5-year survival) within four successive scenarios and asked after each scenario whether they would recommend the screening to a (hypothetical) patient given the data. Options to answer are: Definitely yes, Probably yes, Probably no, Definitely no, Can't decide.
- Number of Physicians (= Participants) Assuming a Benefit of Screening [ Time Frame: 25 minutes (mean duration of the survey) ]Physicians are faced with four different medical statistics about the effect of screening (e.g., 5-year survival) within four successive scenarios and after each scenario asked whether they assume the screening to be beneficial given the statistical information. Options to answer are: yes, no, can't decide. If yes, then participants are further asked to describe this benefit by the following categories: Very large, large, moderate, small, very small.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981019
|Max Planck Institute for Human Development|
|Berlin, Germany, 14195|
|Principal Investigator:||Odette Wegwarth, Dr.||Max Planck Institute for Human Development|